John Vincent Oyler
John Oyler | |
|---|---|
| Born | John Vincent Oyler 1968[1] Pittsburgh, Pennsylvania |
| Alma mater | Massachusetts Institute of Technology |
| Occupation | Businessman |
| Known for | BeiGene |
John V. Oyler (born 1968[1] as John Vincent Oyler) is an American executive.[2] He is known for co-founding BeiGene, a biotechnology company, with biochemist Xiaodong Wang.[3] He also helped establish BioDuro and other companies.
Early life and education
[edit]Oyler grew up in Pittsburgh, Pennsylvania.[1] He attended the Massachusetts Institute of Technology.[4] He graduated with a degree in mechanical engineering[3] in 1990.[5]
Career
[edit]Oyler began his career as a consultant at McKinsey & Company, which often involved traveled to China.[6] During his time at McKinsey, he earned an MBA degree from Stanford University and continued to work there after graduate school.[3]
Oyler joined Genta, a biotechnology company focused on cancer drugs, in 1997. At Genta, Oyler hired new management and grew the company's valuation from a few million dollars to $1.7 billion.[7]
In 1998,[8] Oyler was a founder of Telephia, a telecom research company[6] where he served as president.[9] Nielsen Holdings acquired Telephia in 2007.[10] Oyler was also headed Galenea, a company focused on treatments for psychiatric diseases,[11] from 2002 to 2004.[12]
In 2005, Oyler returned to China[6] and co-founded BioDuro, a contract research organization.[11][7] PPD acquired BioDuro in 2009.[13]
BeiGene
[edit]Oyler co-founded BeiGene in 2010 with Chinese biochemist Xiaodong Wang,[14] whom Oyler met while working at BioDuro.[3][14]
BeiGene has developed two cancer medicines, namely Tevimbra, a checkpoint inhibitor, and Brukinsa, a Bruton's tyrosine kinase inhibitor.[4][15] As of 2023, BeiGene had 10,000 employees.[16]
Personal life
[edit]Oyler is married and has one daughter.[15]
See also
[edit]References
[edit]- ^ a b c Dai, Sarah (16 October 2017). "CEO of China health care start-up works hard on cancer drugs pipeline". South China Morning Post. Retrieved 27 September 2023.
- ^ Forbes profile
- ^ a b c d Wright, Rob (1 November 2019). "How — And Why — John Oyler Built BeiGene". Life Science Leader. Retrieved 26 September 2023.
- ^ a b Henderson, Lisa (29 March 2023). "A Vision of Affordability". PharmExec. Retrieved 27 September 2023.
- ^ "Fireside chat with John Oyler". MIT Club of Hong Kong. Retrieved 27 September 2023.
- ^ a b c Saionz, Amanda (4 May 2023). "In Profile: BeiGene's John Oyler". PharmaBoardroom. Retrieved 26 September 2023.
- ^ a b Tremblay, Jean-François (2008). "China's Pharma Leaps Into Discovery" (PDF). Chemical & Engineering News. Retrieved 26 September 2023.
- ^ Gregson, Reily (30 November 1999). "Telephia Hopes to Become the A.C. Nielsen of Wireless World". RCR Wireless News. Retrieved 26 September 2023.
- ^ Gregson, Reily (30 November 1999). "Telephia expands into untethered Internet access monitoring". RCR Wireless News. Retrieved 26 September 2023.
- ^ Learmonth, Michael (28 June 2007). "Nielsen nabs Telephia". Variety. Retrieved 18 December 2023.
- ^ a b Jia, Hepeng (19 May 2008). "China's one stop research shop". Chemistry World. Retrieved 26 September 2023.
- ^ "John V. Oyler". The Medicine Maker. 2022. Retrieved 27 September 2023.
- ^ "PPD Buys BioDuro For $77 Million". Manufacturing.net. Associated Press. 30 November 2009. Retrieved 26 September 2023.
- ^ a b Loo, Daryl (2011-07-07). "BeiGene Brings Biotech to China". Bloomberg. Retrieved 2020-08-04.
- ^ a b Zhang Liang (11 September 2023). "抗癌新势力：百济神州的颠覆与创新". Harvard Business Review China. Retrieved 27 November 2023.
- ^ "Form 10-Q". BeiGene. 30 June 2023. Retrieved 15 August 2023.